Schedules of Controlled Substances: Placement of Brorphine in Schedule I; Correction, 46073 [2023-15249]
Download as PDF
<![CDATA[
46073
Federal Register / Vol. 88, No. 137 / Wednesday, July 19, 2023 / Rules and Regulations
Country
Entity
*
*
IRELAND ..........
*
NORTH MACEDONIA.
*
*
*
*
*
[FR Doc. 2023–15343 Filed 7–18–23; 8:45 am]
BILLING CODE 3510–33–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–716]
Schedules of Controlled Substances:
Placement of Brorphine in Schedule I;
Correction
Drug Enforcement
Administration, Department of Justice.
ACTION: Final order; correction.
Correcting amendment.
AGENCY:
On March 6, 2023, the Drug
Enforcement Administration published
a final order placing 1-(1-(1-(4bromophenyl)ethyl)piperidin-4-yl)-1,3dihydro-2H-benzo[d]imidazol-2-one
(commonly known as brorphine),
including its isomers, esters, ethers,
salts, and salts of isomers, esters, and
ethers whenever the existence of such
isomers, esters, ethers, and salts is
possible within the specific chemical
designation, in schedule I of the
Controlled Substances Act. In an
amendatory instruction, the document
incorrectly designated certain
paragraphs. This document corrects that
instruction.
DATES: This correcting amendment is
effective July 19, 2023, and is applicable
beginning March 6, 2023.
FOR FURTHER INFORMATION CONTACT: Dr.
Terrence L. Boos, Drug and Chemical
SUMMARY:
ddrumheller on DSK120RN23PROD with RULES1
For all items subject
to the EAR. (See
§ 744.11 of the
EAR).
16:28 Jul 18, 2023
Jkt 259001
For all items subject
to the EAR. (See
§ 744.11 of the
EAR).
*
Federal Register
citation
*
Presumption of denial
*
*
88 FR [INSERT FR
PAGE NUMBER 7/
19/2023].
*
Presumption of denial
*
*
88 FR [INSERT FR
PAGE NUMBER 7/
19/2023].
*
*
Evaluation Section, Diversion Control
Division, Drug Enforcement
Administration; Telephone: (571) 362–
3249.
SUPPLEMENTARY INFORMATION: In FR Doc.
2023–04364, appearing on page 13692
in the Federal Register of Monday,
March 6, 2023 (88 FR 13692), the
following correction is made:
DEPARTMENT OF HOMELAND
SECURITY
§ 1308.11
Special Local Regulation; Iron Man
70.3 Triathlon, Lake Erie; Sandusky,
OH
[Corrected]
1. On page 13694, in the third column,
amendatory instruction number 2 is
corrected to read as follows:
■ ‘‘2. In § 1308.11:
■ a. Redesignate paragraphs (b)(22)
through (b)(92) as (b)(23) through
(b)(93);’’
■ b. Add a new paragraph (b)(22);
■ c. Remove and reserve paragraph
(h)(49).
The addition reads as follows:’’
■
21 CFR Part 1308
License review policy
*
*
*
Thea D. Rozman Kendler,
Assistant Secretary for Export
Administration.
VerDate Sep<11>2014
*
Cytrox AD, a.k.a., the following one alias:
—Sytrox.
October 20, no. 1/1–1 Skopje, Karpos, North Macedonia; and Metropolitan Theodosij Gologanov 44,
Skopje, Karpos, North Macedonia.
*
*
*
Intellexa Limited, a.k.a., the following one alias:
—Intellexa Ltd.
3rd Floor, Ulysses House, Foley Street, Dublin 1,
Dublin, Ireland, D01W2T2.
*
*
License requirement
Signing Authority
This document of the Drug
Enforcement Administration was signed
on July 5, 2023, by Administrator Anne
Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
document in electronic format for
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2023–15249 Filed 7–18–23; 8:45 am]
BILLING CODE P
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
Coast Guard
33 CFR Part 100
[Docket Number USCG–2023–0536]
RIN 1625–AA08
Coast Guard, DHS.
Temporary final rule.
AGENCY:
ACTION:
The Coast Guard will
establish and enforce a special local
regulation for the Ironman 70.3 Ohio
Triathlon from 4:30 a.m. through 10
a.m. on July 23. 2023. This special local
regulation is necessary to safely control
vessel movements in the vicinity of the
triathlon and provide for the safety of
the general boating public and
commercial shipping. During this
enforcement period, no person or vessel
may enter the regulated area without the
permission of the Coast Guard Patrol
Commander.
SUMMARY:
This special local regulation will
be enforced from 4:30 a.m. through 10
a.m. on July 23, 2023.
ADDRESSES: To view documents
mentioned in this preamble as being
available in the docket, go to https://
www.regulations.gov, type USCG–2023–
0536 in the ‘‘SEARCH’’ box and click
‘‘SEARCH.’’ Next, in the Document
Type column, select ‘‘Supporting &
Related Material.’’
FOR FURTHER INFORMATION CONTACT: If
you have questions on this rule, call or
email the Command Duty Officer, MST1
Karl Dirksmeyer, Marine Safety Unit
DATES:
E:\FR\FM\19JYR1.SGM
19JYR1
]]>Agencies
[Federal Register Volume 88, Number 137 (Wednesday, July 19, 2023)]
[Rules and Regulations]
[Page 46073]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15249]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-716]
Schedules of Controlled Substances: Placement of Brorphine in
Schedule I; Correction
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order; correction. Correcting amendment.
-----------------------------------------------------------------------
SUMMARY: On March 6, 2023, the Drug Enforcement Administration
published a final order placing 1-(1-(1-(4-bromophenyl)ethyl)piperidin-
4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as
brorphine), including its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers whenever the existence of such isomers,
esters, ethers, and salts is possible within the specific chemical
designation, in schedule I of the Controlled Substances Act. In an
amendatory instruction, the document incorrectly designated certain
paragraphs. This document corrects that instruction.
DATES: This correcting amendment is effective July 19, 2023, and is
applicable beginning March 6, 2023.
FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and
Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION: In FR Doc. 2023-04364, appearing on page
13692 in the Federal Register of Monday, March 6, 2023 (88 FR 13692),
the following correction is made:
Sec. 1308.11 [Corrected]
0
1. On page 13694, in the third column, amendatory instruction number 2
is corrected to read as follows:
0
``2. In Sec. 1308.11:
0
a. Redesignate paragraphs (b)(22) through (b)(92) as (b)(23) through
(b)(93);''
0
b. Add a new paragraph (b)(22);
0
c. Remove and reserve paragraph (h)(49).
The addition reads as follows:''
Signing Authority
This document of the Drug Enforcement Administration was signed on
July 5, 2023, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-15249 Filed 7-18-23; 8:45 am]
BILLING CODE P
